<SEC-DOCUMENT>0001213900-23-005123.txt : 20230125
<SEC-HEADER>0001213900-23-005123.hdr.sgml : 20230125
<ACCEPTANCE-DATETIME>20230125161549
ACCESSION NUMBER:		0001213900-23-005123
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230125
FILED AS OF DATE:		20230125
DATE AS OF CHANGE:		20230125

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SciSparc Ltd.
		CENTRAL INDEX KEY:			0001611746
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38041
		FILM NUMBER:		23552645

	BUSINESS ADDRESS:	
		STREET 1:		20 RAUL WALLENBERG STREET, TOWER A
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916
		BUSINESS PHONE:		972-3-6103100

	MAIL ADDRESS:	
		STREET 1:		20 RAUL WALLENBERG STREET, TOWER A
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SciSparc Ltd./ADR
		DATE OF NAME CHANGE:	20210129

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Therapix Biosciences Ltd.
		DATE OF NAME CHANGE:	20140624
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea172182-6k_scisparc.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Report of Foreign Private Issuer<BR>
Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of January 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Report No. 4)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission file number: 001-38041</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SCISPARC LTD.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>20 Raul Wallenberg Street, Tower A,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Tel Aviv 6971916 Israel</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT>
Form 40-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 25, 2023, SciSparc
Ltd. (the &ldquo;Company&rdquo;) issued a press release <FONT STYLE="background-color: white">titled &ldquo;SciSparc Announces Corporate
Restructuring Plan.&rdquo;</FONT> A copy of this press release is furnished herewith as Exhibit 99.1 and incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The press release attached
hereto as Exhibit 99.1 is incorporated by reference into the Company&rsquo;s registration statements on Form F-3 (File No. <U><A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390022037966/ea162219-f3_scisparcltd.htm">333-266047</A></U>,
File No. <U><A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390019016952/ff32019a1_therapixbio.htm">333-233417</A></U> and File No. <U><A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390022022376/ea158932-posam_scisparcltd.htm">333-248670</A></U>) and on Form S-8 (File No. <U><A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390018008005/fs82018_therapixbiosciences.htm">333-225773</A></U>) filed with the Securities and
Exchange Commission to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or
reports subsequently filed or furnished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT INDEX</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid"><B>Exhibit No.</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: justify">99.1</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea172182ex99-1_scisparc.htm">Press Release issued by SciSparc Ltd. on January 25, 2023 titled &ldquo;<FONT>SciSparc Announces Corporate Restructuring Plan</FONT>.&rdquo;</A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%"><B>SciSparc Ltd.</B></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">Date: January 25, 2023</TD>
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 35%">/s/ Oz Adler</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:&nbsp;</TD>
    <TD>Oz Adler</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD STYLE="text-align: justify">Chief Executive Officer and<BR>
Chief Financial Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea172182ex99-1_scisparc.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY SCISPARC LTD. ON JANUARY 25, 2023 TITLED "SCISPARC ANNOUNCES CORPORATE RESTRUCTURING PLAN."
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="text-align: right; margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: left; font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>SciSparc Announces Corporate Restructuring
plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>SciSparc will examine
the possibility of a public listing for its pharmaceutical activity while retaining a controlling interest</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">TEL AVIV, Israel, Jan. 25, 2023 (GLOBE NEWSWIRE)
-- SciSparc Ltd. (Nasdaq: SPRC) (&ldquo;Company&rdquo; or &ldquo;SciSparc&rdquo;), a specialty clinical-stage pharmaceutical company focusing
on the development of therapies to treat disorders of the central nervous system, announced today that its board of directors has resolved
on pursuing a restructuring plan which involves transferring its pharmaceutical activities to a new wholly owned subsidiary.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white">As part of the plan, SciSparc will examine
the possibility of listing this new subsidiary on a leading stock exchange, while maintaining its control interest. The reorganized structure
will allow the Company to continue to control its current activities.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white">In addition, the Company will explore other
potential new opportunities, activities and investments in a variety of sectors.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">This press release is not an offer of securities
for sale in the United States or any other jurisdiction. Securities may not be offered or sold in the United States absent registration
or an exemption from registration. Any public offering of securities to be made in the United States will be made by means of a prospectus
that may be obtained from the issuer or the selling security holder which will contain detailed information about the issuer, its management
as well as financial statements.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>About SciSparc Ltd. (Nasdaq: SPRC):</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">SciSparc Ltd. is a specialty clinical-stage
pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc&rsquo;s focus is on creating and enhancing
a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the
following drug development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 for the treatment of Tourette Syndrome,
for the treatment of Alzheimer&rsquo;s disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum
disorder and status epilepticus.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Forward-Looking Statements:</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">This press release contains forward-looking
statements within the meaning of the &ldquo;safe harbor&rdquo; provisions of the Private Securities Litigation Reform Act of 1995 and
other Federal securities laws. For example, SciSparc is using forward-looking statements when it discusses its restructuring plan which
involves transferring its pharmaceutical activities to a new wholly owned subsidiary; the possible stock exchange listing of such subsidiary;
the Company&rsquo;s plan to retain a controlling interest in its pharmaceutical activities; and exploring other potential new opportunities,
activities and investments. Because such statements deal with future events and are based on SciSparc&rsquo;s current expectations, they are
subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those
described in or implied by the statements in this press release. The forward- looking statements contained or implied in this press release
are subject to other risks and uncertainties, including those discussed under the heading &ldquo;Risk Factors&rdquo; in SciSparc&rsquo;s Annual
Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on April 28, 2022, and in subsequent
filings with the SEC. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking
statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or
otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Investor Contact:<BR>
</B>IR@scisparc.com<BR>
Tel: +972-3-6167055</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "6 *H# 2(  A$! Q$!_\0
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M4\0:1J'B+Q'8V,T.S0;7%U.Y8?Z1(#\L>.N!U.:ZQ1M&,8% #J*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHJIJ&J66DVCW>H7,5M;H,M)*P44
M 6STKFSXI6Y\5+H6FVQNVAYOIU/R6W'"D]VSVK7T_4;76=,BO+1F:VN%)1BI
M4D=.AYJ+1-"T[P]IZV.F6R06ZDL0.2Q)R2Q/)/N: -&EHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "N=USQ?:Z)?+8FQU"[NF0.L=K;LX(/^UT'3
MUKHJ0J"<]Z ,W1-3NM4L3<76F3Z>Q8A8IR"Q7L3CI]*I7/@W1[[7_P"V;^*2
M\N% $4=RY>*''=$/ /OUK?Q2T -5 H & !T IU%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
